Correct. Historically the FDA have always put efficacy above safety. Efficacy with some side effects trumps no side effects with limited efficacy. So with that argument in mind the deciding question put to ODAC is the one the FDA wanted a definitive answer for - Does it work?
FDA does not over-rule positive ODAC decisions, page-11
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.3¢ |
Change
-0.018(1.86%) |
Mkt cap ! $1.061B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.0¢ | 91.8¢ | $1.708M | 1.845M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 269673 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 209495 | 26 |
View Market Depth
| Last trade - 15.54pm 16/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |